Drugs / quaratusugene ozeplasmid
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05062980 | Mar 2022 → Feb 2025 | non-small cell lung carcinoma | Genprex, Inc. | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05703971 | May 2024 → Jun 2026 overdue | small cell lung carcinoma | Genprex, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04486833 | Sep 2021 → Mar 2028 expected | non-small cell lung carcinoma | Genprex, Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quaratusugene ozeplasmid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04486833 ↗ |
| Known as | Oncoprex | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594390 ↗ |
| Action | Restore | “reestablishing pathways that promote cancer cell death” NCT04486833 ↗ |
| Modality | Other / unclassified | “experimental nonviral immunogene therapy” NCT05703971 ↗ |
| Route | Intravenous | “intravenous administration once every 21 days” NCT04486833 ↗ |
| Target | TUSC2 | “utilizing the TUSC2 gene” NCT05703971 ↗ |